Value-based pricing 'will not improve' cancer drug access
Government proposals to introduce a value-based pricing system for new drugs will not significantly improve patient access to treatments, experts have warned.
Continue reading this article – simply subscribe below
Subscribing takes two minutes and you’ll immediately have full access to hsj.co.uk, plus the HSJ magazine delivered every week.
HSJ Subscribers:
If you are a Health Service Journal subscriber please sign in with your email address and click submit:
Not yet a subscriber?
Sign up today for immediate access to hsj.co.uk and Health Service Journal magazine
Alternatively, try our 14-day free trial subscription
